Inactive Instrument

News Arch Therapeutics, Inc. Other OTC

Equities

ARTH

US03939W1099

Summary

Unlock all the news: Be the first to know and act before the market!

Arch Therapeutics, Inc. announced that it has received $5.058 million in funding from Drake Partners, LLC, Oasis Capital, LLC	Jun. 29	CI
Arch Therapeutics, Inc. announced that it has received $0.15 million in funding	Jun. 11	CI
Arch Therapeutics, Inc. announced that it has received $1.85 million in funding	May. 14	CI
Arch Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	May. 09	CI
Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Spring Meeting (SAWC Spring)	May. 06	AQ
Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Spring Meeting (SAWC Spring)	May. 06	CI
Arch Therapeutics : New Financial Obligation - Form 8-K	Apr. 03	PU
Arch Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 20	CI
Arch Therapeutics, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	Feb. 15	CI
Arch Therapeutics : New Financial Obligation - Form 8-K	Dec. 15	PU
Arch Therapeutics Provides Year End Operational Update	Nov. 09	AQ
Arch Therapeutics to Present AC5® Advanced Wound System at the 2023 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)	Nov. 02	AQ
Arch Therapeutics, Inc. to Present AC5®? Advanced Wound System at the 2023 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)	Nov. 02	CI
Arch Therapeutics, Inc. Provides Commercialization Update on the First Product, AC5 Advanced Wound System	23-09-13	CI
Arch Therapeutics Provides AC5® Commercialization Update	23-09-13	AQ
Arch Therapeutics Completes Financing as Bridge to Uplisting	23-09-07	AQ
Arch Therapeutics, Inc. announced that it has received $2.560063 million in funding	23-08-30	CI
Arch Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-11	CI
Arch Therapeutics, Inc. announced that it expects to receive $1.850001 million in funding	23-07-06	CI
Arch Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Arch Therapeutics, Inc. Other OTC

Equities

ARTH

US03939W1099

Summary

Filters